Story preview
Continue reading on the publisher site for the full article.
Read on publisher →The Globe and Mail
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
11
in the last 3 days
First reported
4 days ago
10 outlets since
Countries
10 other outlets reported this story in the last 3 days.
Eli Lilly spent most of its 150-year history as a quiet insulin maker before a single drug reshuffled the entire obesity market and turned a modest stake into a fortune that left the S&P 500 in the dust. The question now is whether the next chapter repeats that run or breaks it.
Eli Lilly (LLY:NYSE) stock rose roughly 4% on Wednesday, October 14, joining a broad rally in healthcare stocks. No major Lilly news drove it.
TradingKey - Dell stock forecast: DELL tests $452 support after a 17% two-day drop on a Barclays downgrade, while a $95 billion AI backlog keeps the bull case alive.